Redefining precision in cancer Treatment: A novel electrochemical approach using bimetal oxide composites for Niraparib quantification

Amidst the accelerating global surge in cancer incidences, there has been a parallel increase in worldwide efforts to propel the development of advanced therapeutic agents, and the role of poly(ADP-ribose)polymerase (PARP) inhibitors like Niraparib (NRP) has emerged as significant. NRP, approved by the FDA for treating certain ovarian cancers, requires precise and sensitive detection techniques to mitigate potential toxicities. Existing methods such as HPLC-UV, LC-MS/MS, and UPLC-MS/MS are often complex and expensive. In light of this, this study pioneered the development of a new electrochemical sensor utilizing a novel bimetal oxide composite to modify the bare glassy carbon electrode (GCE) to detect NRP efficiently. The bimetal oxide composite, comprised of ruthenium (IV) oxide (RuO2) and bismuth (III) oxide (Bi2O3), is designed to enhance the electrochemical per-formance of the electrode by offering superior redox (Faradaic) reactions and electrical conductivity. The implemented analytical strategy employed precision differential pulse voltammetry (DPV), conducted under rigorously controlled conditions to evaluate the sensor's performance. Subsequent assessments established a linear response range for NRP determination, spanning 0.1 to 9.39 mu M, with a correlation equation denoted as I = 0.243CNRP + 0.261 and an associated coefficient of determination (R2) of 0.990. This allowed for the discernment of the limit of detection (LOD) at 0.037 mu M and the limit of quantification (LOQ) at 0.12 mu M for NRP. Significantly, the electrochemical sensor developed herein demonstrated robust efficacy in quantifying NRP in pharmaceutical formulations and urine samples, affirming its potential application in clinical practice. This research heralds a new era in the analytical pursuit of cancer therapeutics, providing an accessible, cost-effective, and reliable alternative for detecting and monitoring Niraparib, thereby contributing to the broader landscape of personalized oncology treatment.